Agios Pharmaceuticals reported a quarterly loss of $1.69 per share, better than the Zacks Consensus Estimate for a loss of $1.81 and improved from a loss of $1.55 per share a year ago. The small earnings beat is modestly supportive, but the headline remains a net loss and is unlikely to be a major market mover on its own.
Agios Pharmaceuticals reported a quarterly loss of $1.69 per share, better than the Zacks Consensus Estimate for a loss of $1.81 and improved from a loss of $1.55 per share a year ago. The small earnings beat is modestly supportive, but the headline remains a net loss and is unlikely to be a major market mover on its own.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
